|Description:||1. Pterosin A is a novel activator of adenosine monophosphate-activated protein kinase, which is crucial for regulating blood glucose homeostasis,
2. Pterosin A has potential anti-diabetic activity, it can significantly reverse the increased serum insulin and insulin resistance (IR) in dexamethasone-IR mice and in db/db mice. |
|Targets:||ROS | GLUT | AMPK | Akt | p38MAPK | GSK-3|
|Source:||The herbs of Pteris aquilinum|
|Solvent:||Chloroform, Dichloromethane, Ethyl Acetate, DMSO, Acetone, etc.|
|Storage:||Providing storage is as stated on the product vial and the vial is kept tightly sealed, the product can be stored for up to 24 months(2-8C).
Wherever possible, you should prepare and use solutions on the same day. However, if you need to make up stock solutions in advance, we recommend that you store the solution as aliquots in tightly sealed vials at -20C. Generally, these will be useable for up to two weeks. Before use, and prior to opening the vial we recommend that you allow your product to equilibrate to room temperature for at least 1 hour.
Need more advice on solubility, usage and handling? Please email to: email@example.com
|After receiving:||The packaging of the product may have turned upside down during transportation, resulting in the natural compounds adhering to the neck or cap of the vial. take the vial out of its packaging and gently shake to let the compounds fall to the bottom of the vial. for liquid products, centrifuge at 200-500 RPM to gather the liquid at the bottom of the vial. try to avoid loss or contamination during handling.|
|1 mg||5 mg||10 mg||20 mg||25 mg|
|1 mM||4.03 mL||20.1499 mL||40.2998 mL||80.5997 mL||100.7496 mL|
|5 mM||0.806 mL||4.03 mL||8.06 mL||16.1199 mL||20.1499 mL|
|10 mM||0.403 mL||2.015 mL||4.03 mL||8.06 mL||10.075 mL|
|50 mM||0.0806 mL||0.403 mL||0.806 mL||1.612 mL||2.015 mL|
|100 mM||0.0403 mL||0.2015 mL||0.403 mL||0.806 mL||1.0075 mL|
Int J Mol Sci. 2015 Jan 22;16(2):2497-516.
|Chemical constituents analysis and antidiabetic activity validation of four fern species from Taiwan.[Pubmed: 25622260]|
|Pterosins are abundant in ferns, and Pterosin A was considered a novel activator of adenosine monophosphate-activated protein kinase, which is crucial for regulating blood glucose homeostasis. However, the distribution of pterosins in different species of ferns from various places in Taiwan is currently unclear. To address this question, the distribution of pterosins, glucose-uptake efficiency, and protective effects of Pterosin A on β-cells were examined. Our results showed that three novel compounds, 13-chloro-spelosin 3-O-β-d-glucopyranoside (1), (3R)-Pterosin D 3-O-β-d-(3'-p-coumaroyl)-glucopyranoside (2), and (2R,3R)-Pterosin L 3-O-β-d-(3'-p-coumaroyl)-glucopyranoside (3), were isolated for the first time from four fern species (Ceratopteris thalictroides, Hypolepis punctata, Nephrolepis multiflora, and Pteridium revolutum) along with 27 known compounds. We also examined the distribution of these pterosin compounds in the mentioned fern species (except N. multiflora). Although all Pterosin Analogs exhibited the same effects in glucose uptake assays, Pterosin A prevented cell death and reduced reactive oxygen species (ROS) production. This paper is the first report to provide new insights into the distribution of pterosins in ferns from Taiwan. The potential anti-diabetic activity of these novel phytocompounds warrants further functional studies.|
Diabetes. 2013 Feb;62(2):628-38.
|Antidiabetic effects of pterosin A, a small-molecular-weight natural product, on diabetic mouse models.[Pubmed: 23069626 ]|
|The therapeutic effect of Pterosin A, a small-molecular-weight natural product, on diabetes was investigated. Pterosin A, administered orally for 4 weeks, effectively improved hyperglycemia and glucose intolerance in streptozotocin, high-fat diet-fed, and db/db diabetic mice. There were no adverse effects in normal or diabetic mice treated with Pterosin A for 4 weeks. Pterosin A significantly reversed the increased serum insulin and insulin resistance (IR) in dexamethasone-IR mice and in db/db mice. Pterosin A significantly reversed the reduced muscle GLUT-4 translocation and the increased liver phosphoenolpyruvate carboxyl kinase (PEPCK) expression in diabetic mice. Pterosin A also significantly reversed the decreased phosphorylations of AMP-activated protein kinase (AMPK) and Akt in muscles of diabetic mice. The decreased AMPK phosphorylation and increased p38 phosphorylation in livers of db/db mice were effectively reversed by Pterosin A. Pterosin A enhanced glucose uptake and AMPK phosphorylation in cultured human muscle cells. In cultured liver cells, Pterosin A inhibited inducer-enhanced PEPCK expression, triggered the phosphorylations of AMPK, acetyl CoA carboxylase, and glycogen synthase kinase-3, decreased glycogen synthase phosphorylation, and increased the intracellular glycogen level. These findings indicate that Pterosin A may be a potential therapeutic option for diabetes.|